Optimizing Biologic Agents in Ulcerative Colitis and Crohn’s Disease

Current Gastroenterology Reports

Volumn 17, Issue 8, 2015, Pages

  O’Toole, Aoibhlinn ^a   Moss, Alan C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adalimumab; Antibodies; Biologics; Crohn s disease; Inflammatory bowel disease; Infliximab; Therapeutic drug monitoring; Trough levels; Ulcerative colitis

Indexed keywords

ADALIMUMAB; ANRUKINZUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; ETROLIZUMAB; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; NATALIZUMAB; PLACEBO; PREDNISONE; USTEKINUMAB; VEDOLIZUMAB; BIOLOGICAL FACTOR;

BIOLOGICAL THERAPY; CROHN DISEASE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; REMISSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT RESPONSE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; PROCEDURES;

ADALIMUMAB; BIOLOGICAL FACTORS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG MONITORING; DRUG SUBSTITUTION; EVIDENCE-BASED MEDICINE; HUMANS; INFLIXIMAB;

EID: 84938838849     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-015-0453-1     Document Type: Review

References (75)

1. Plevy SE, Targan SR. Anti-tumor necrosis factor-alpha therapy in Crohn’s disease: a magic bullet finally hits its mark. Inflamm Bowel Dis. 1996;2(2):158–9.
2. Costa J et al. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013;19(10):2098–110.
3. Chen JS et al. Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis. Arthritis Care Res (Hoboken). 2014;66(3):464–72.
4. Kestens C et al. Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-alpha agents. Clin Gastroenterol Hepatol. 2013;11(7):826–31.
5. Osterman MT et al. Comparative effectiveness of infliximab and adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(5):811–7.e3.
6. Patil SA et al. Comparative effectiveness of anti-TNF agents for Crohn’s disease in a tertiary referral IBD practice. Dig Dis Sci. 2013;58(1):209–15.
7. Sandborn WJ et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–25.
8. Feagan BG et al. Treatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370–7.
9. Sandborn WJ et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–21.
10. Van Assche G et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med. 2005;353(4):362–8.
11. Benson JM et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–45.
12. Sandborn WJ, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 367(16):1519–28.
13. Kopylov U, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease-the McGill experience. J Crohns Colitis. 2014.
14. Rutgeerts P. How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD? Dig Dis. 2012;30(4):396–9.
15. Hanauer SB et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–9.
16. Lichtenstein GR et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology. 2005;128(4):862–9.
17. Feagan BG et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology. 2008;135(5):1493–9.
18. Colombel JF et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–95. First randomized trial to determine the impact of concurrent immunomodulator therapy on outcomes with Infliximab.
19. Peyrin-Biroulet L et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut. 2011;60(7):930–6.
20. Reinisch W et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–7.
21. Sandborn WJ et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257–65.e1-3.
22. Rutgeerts P et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–76.
23. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–35.
24. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1756–67.
25. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104(3):760–7.
26. Steenholdt C et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63(6):919–27. Prospectively examined the impact of measuring drug levels on costs and outcomes in patients who lose response to anti-TNFs.
27. Baert F et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8.
28. O’Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(1):1–6.
29. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40–7. quiz 48.
30. Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(1):63–8.
31. Peyrin-Biroulet L et al. First-line therapy in adult Crohn’s disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol. 2013;10(6):345–51.
32. Ruemmele FM, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014.
33. Schreiber S et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013;7(3):213–21.
34. Schreiber S et al. Increased response and remission rates in short-duration Crohn’s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105(7):1574–82.
35. D’Haens G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7. Assessed the impact of early combined therapy on mucosal healing in patients recently diagnosed with Crohn’s disease.
36. Peyrin-Biroulet L et al. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol. 2010;105(2):289–97.
37. Sands BE et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2001;7(2):83–8.
38. Gardiner KR et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 1995;36(6):897–901.
39. Kevans D, Murthy S, Iacono A, Silverberg MS, Greenberg GR. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology. 2012;142(Issue 5, Supplement 1):S-384–5.
40. Brandse JF, et al. 157 fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. Gastroenterology. 144(5):S-36.
41. Ordas I et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46.
42. Fasanmade AA et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297–308. Demonstrates the role of pharmacokinetics of anti-TNFs in determining clinical outcomes in IBD.
43. Wolbink GJ et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704–7.
44. Adedokun OJ, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014.
45. Gibson DJ, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2014. Small study that suggests a major impact on colectomy rates from accelerated dosing of infliximab in severe colitis.
46. Khanna R, Levesque BG, Bressler B, Zou G, Stitt L, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn’s disease: a community-based cluster randomized trial. J Crohn’s Colitis. 2014;8(Supplement 1):S2.
47. Abraham NS et al. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(10):1281–7.
48. Panaccione R et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3.
49. Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40(4):338–53.
50. Sokol H et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut. 2010;59(10):1363–8.
51. Bouguen G et al. Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(8):975–81.e1-4.
52. Reenaers C et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab? Aliment Pharmacol Ther. 2012;36(11–12):1040–8.
53. Feagan BG et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–688.e1.
54. Devlin SM, Cheifetz AS, Siegel CA. Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor alpha agents for inflammatory bowel disease. Gastroenterol Clin N Am. 2012;41(2):411–28.
55. Kotlyar DS et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1.
56. Deepak P et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108(1):99–105.
57. Yanai H, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2014. Demonstrates that changing drug class is more effective than dose escalation in patients who have adequate drug levels or high anti-drug antibodies.
58. Lichtenstein GR et al. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107(9):1409–22.
59. Lichtenstein GR et al. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT Registry. Am J Gastroenterol. 2014;109(2):212–23.
60. Lin Z, Bai Y, Zheng P. Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn’s disease. Eur J Gastroenterol Hepatol. 2011;23(12):1100–10.
61. Colombel JF et al. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(2):349–58.
62. Chaparro M et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011;45(2):113–8.
63. Cornillie F, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014.
64. Drobne D, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014.
65. Paul S et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19(12):2568–76.
66. Afif W et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009;15(9):1302–7.
67. Vande Casteele N et al. OP11 Individualised infliximab treatment using therapeutic drug monitoring: a prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. J Crohn’s Colitis. 2012;6:S6.
68. Vande Casteele N, Gils A, Ballet V, Compernolle G, Peeters M, Van Steen K, Simoens S, Ferrante M, Van Assche G, Vermeire S, Rutgeerts P. Randomised controlled trial of drug level versus clinically based dosing of infliximab maintenance therapy in IBD: final results of the taxit study. In United European Gastroenterology (UEG) Week location:Berlin date:12–16 October 2013. 2013.
69. Baert F et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis. 2013;7(2):154–60.
70. Vaughn BP et al. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003. First study to report improved clinical benefits when serum biologic levels are monitered in a pro-active manner, rather than in a reactive manner to loss of response.
71. Miheller P et al. Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use? Expert Opin Biol Ther. 2012;12(2):179–92.
72. Moss AC. Therapeutic drug monitoring, mucosal healing, deep remission: the path to nirvana in Crohn’s disease? Clin Gastroenterol Hepatol. 2014;12(3):432–3.
73. Vande Casteele N et al. Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther. 2013;37(10):1024–5.
74. Frederiksen MT, et al. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD. Inflamm Bowel Dis. 2014.
75. Van Assche G et al. Switch to adalimumab in patients with Crohn’s disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 2012;61(2):229–34.